Phlow Corp.


Phlow Corp. is a U.S.-based public benefit corporation dedicated to reimagining essential medicines through innovative manufacturing processes, including flow chemistry, to provide affordable, high-quality, and domestically produced medicines. The company aims to strengthen the U.S. pharmaceutical supply chain, reduce dependency on foreign manufacturing, and ensure access to critical medicines for Americans.

Industries

chemical
health-care
manufacturing
pharmaceutical

Nr. of Employees

medium (51-250)


Products

Onshore API production and finished pharmaceutical products

Production of essential small-molecule APIs and finished dosage forms manufactured in U.S. facilities to supply clinical and commercial demand.


Services

Contract development and manufacturing of active pharmaceutical ingredients and finished pharmaceutical products at U.S.-based facilities for government and commercial customers.

Laboratory analytical testing, process analytical technology development, and AI-enabled data analysis to support manufacturing quality and process optimization.

Support for technology transfer from R&D to manufacturing, post-transfer verification, method validation, and preparation for regulatory submissions aligned with pharmacopeial standards.

Operational management of a strategic domestic API reserve and ability to ramp production to meet surge demand for essential medicines and medical countermeasures.

Expertise Areas

  • Advanced continuous-flow pharmaceutical manufacturing
  • Small-molecule API synthesis and scale-up
  • Finished dosage formulation and production
  • Analytical method development and laboratory testing
  • Show More (5)

Key Technologies

  • Flow chemistry / continuous manufacturing
  • Green chemistry process design
  • AI-driven analytical systems
  • Laboratory-based analytical testing and process analytics
  • Show More (2)

News & Updates

Phlow was recognized as a Crisis Innovator at the Inno on Fire awards, celebrating its efforts in pharmaceutical manufacturing and supply chain resilience.

Phlow announced over $35 million in Series B funding to improve the U.S. medicine supply chain.

Phlow expands its analytical capabilities and adopts AI-driven systems to modernize medicine manufacturing in America.

Phlow achieved a key milestone toward full American-made epinephrine production, validating a cost-competitive process.

Phlow secured a $354 million contract to manufacture medicines for Covid-19, aiming to boost domestic drug production.

Dr. Eric Edwards, CEO of Phlow, discusses the $354 million contract to produce Covid-19 medications.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.